Click the blue text above to follow Alzheimer’s disease for free now
Brain Chemistry Laboratory April 21st news
From the Brain Chemistry Laboratory in Jackson Hole (Brain Chemistry Laboratory) Chemistry Labs) researchers identified a biomarker from blood samples that reliably differentiated samples from patients with early Alzheimer’s disease from controls, published in Public Science Libraries: Comprehensive” (PLOS ONE) magazine.
Research published in PLOS ONE on April 21, 2022 (latest impact factor): >
Although the symptoms of advanced Alzheimer’s disease are well known, diagnosing Alzheimer’s disease at an early stage requires careful cognitive testing by a neurologist.
The discovery of unique ratios of metabolites in blood samples from patients with early Alzheimer’s disease promises to speed up diagnosis, allowing early treatment to be initiated.
“We were pleased to find that the ratio of 2-aminoethyl dihydrogen phosphate and taurine concentrations of two molecules Allows us to reliably distinguish samples from patients with early Alzheimer’s disease from controls,” said study lead author Sandra Banack, PhD, a senior scientist in the Jackson Hole Brain Chemistry Laboratory.
Dr. Sandra Banack
strong
25 early participants included Alzheimer’s disease patients and 25 healthy controls. Blood samples were taken from patients enrolled in an FDA-approved Phase II clinical trial at Dartmouth–Hitchcock Medical Center (DHMC) in New Hampshire and shipped to a brain chemistry laboratory for analysis.
Current attempts to diagnose Alzheimer’s disease from blood samples depend on the presence of amyloid fragments and phosphorylated tau, the molecules that cause plaques and tangles in the brain. Knot.
“In the Brain Chemistry Lab, we think amyloid plaques are the result, not the cause, of Alzheimer’s disease,” Brain “What’s exciting about this new finding is that it is independent of amyloid and can be detected on analytical equipment that already exists in most large hospitals,” explained Dr. Paul Alan Cox, Executive Director of the Chemistry Laboratory. /strong>.”
Paul Alan CoxDirector
Used by researchers Two different analytical platforms: amino acid analyzer and tandem mass spectrometry, compared plasma metabolites in patients with early Alzheimer’s disease and healthy controls. They measured the concentrations of 2-aminoethyl dihydrogen phosphate and taurine in the plasma samples. The results of the study found that plasma concentrations of the phospholipid metabolite 2-aminoethyl dihydrogen phosphate, normalized by taurine concentrations, could reliably identify patients with early AD.
A Possible Blood Plasma Biomarker for Early-stage Alzheimer’s Disease, co-authored with Alzheimer’s disease expert Dr. Aleksandra Stark Alzheimer’s Disease) in the journal PLOS ONE.
“
Brain Chemistry Laboratory established in 2006
Brain Chemistry Laboratory (Brain Chemistry Labs) is a non-profit research organization headquartered in Jackson Hole, Wyoming, dedicated to discovering new treatments from plants to improve Alzheimer’s disease, Prognosis in patients with ALS and other neurodegenerative diseases.
References
Source: Brain Chemistry Labs
New Alzheimer’s biomarker may facilitate rapid diagnosis
Reference:
p>
Banack SA, Stark AC, Cox PA (2022) A possible blood plasma biomarker for early-stage Alzheimer’s disease. PLoS ONE 17(4): e0267407. https://doi.org/10.1371/journal.pone .0267407
Disclaimer
The medical information on this official account is provided and shared only as an information resource, and is not used or relied on for any diagnostic or therapeutic purpose. This information should not be used as a substitute for professional diagnosis or treatment. Please consult your doctor before making any medical decision or guidance regarding a specific medical condition.
Caring for parents and paying attention to “Alzheimer’s disease”